MNPR - Monopar Therapeutics Inc Stock Price, Fair Value and News

$77.54+1.60 (+2.11%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MNPR Price Action

Last 7 days

-11.2%

Last 30 days

-7.7%

Last 90 days

99.6%

Trailing 12 Months

234.7%

MNPR RSI Chart

MNPR Valuation

Market Cap

518.2M

Price/Earnings (Trailing)

-26.65

EV/EBITDA

-29.99

Price/Free Cashflow

-47.85

MarketCap/EBT

-37.47

MNPR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MNPR Fundamentals

MNPR Revenue

MNPR Earnings

Earnings (TTM)

-19.4M

Earnings Growth (Yr)

-163.56%

Earnings Growth (Qtr)

-40.11%

MNPR Profitability

Return on Equity

-13.73%

Return on Assets

-13.48%

Free Cashflow Yield

-2.09%

MNPR Investor Care

Shares Dilution (1Y)

26.62%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2021	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Monopar Therapeutics Inc

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo EspaÃƒÆ’Ã‚Â±ol de InvestigaciÃƒÆ’Ã‚Â³n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

CEO	Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
WEBSITE	monopartx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	11

Monopar Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Monopar Therapeutics Inc? What does MNPR stand for in stocks?

MNPR is the stock ticker symbol of Monopar Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Monopar Therapeutics Inc (MNPR)?

As of Wed Dec 03 2025, market cap of Monopar Therapeutics Inc is 518.17 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MNPR stock?

You can check MNPR's fair value in chart for subscribers.

Is Monopar Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether MNPR is over valued or under valued. Whether Monopar Therapeutics Inc is cheap or expensive depends on the assumptions which impact Monopar Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MNPR.